Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Nightingale Health

1.44 EUR

-0.69 %

4,679 following
Corporate customer

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
-0.69 %
-12.20 %
-29.76 %
-34.10 %
-38.98 %
-47.06 %
+12.15 %
-
-72.04 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
87.75M EUR
Turnover
119K EUR
P/E (adj.) (26e)
-5.44
EV/EBIT (adj.) (26e)
-2.87
P/B (26e)
1.65
EV/S (26e)
5.98
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
1.70 EUR
Updated
05.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 06.03.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Nightingale H1'26: Research projects accelerate H2
Research22 hours ago by
Antti Siltanen

Nightingale H1'26: Research projects accelerate H2

Nightingale's major research projects will generate revenue in H2.

Nightingale Health
Nightingale, Webcast, Half-year financial report 1 July–31 December 2025
Webcastyesterday

Nightingale, Webcast, Half-year financial report 1 July–31 December 2025

Nightingale Health
Regulatory press release3/5/2026, 7:00 AM

Nightingale Health's half-year report: Delivering clinical value for healthcare and moving toward 50% revenue growth, supported by a strong sales pipeline

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Nightingale H1'26 preview: Revenue still relies on research projects
Analyst Comment3/3/2026, 7:11 AM by
Antti Siltanen

Nightingale H1'26 preview: Revenue still relies on research projects

We expect revenue to grow, driven by research projects and the Terveystalo collaboration.

Nightingale Health
A step forward for Nightingale in New York
Analyst Comment2/10/2026, 6:50 AM by
Antti Siltanen

A step forward for Nightingale in New York

The New York laboratory permit allows tests to be offered to healthcare providers without separate FDA approval.

Nightingale Health
Regulatory press release2/9/2026, 7:30 PM

Inside information: Nightingale Health achieves major milestone in the United States: New York laboratory now holds a clinical laboratory permit from New York State

Nightingale Health
Another welfare services country is piloting Nightingale's technology
Analyst Comment12/18/2025, 5:54 PM by
Antti Luiro, Antti Siltanen

Another welfare services country is piloting Nightingale's technology

The North Karelia wellbeing services county is piloting Nightingale's blood analysis technology.

Nightingale Health
Press release12/18/2025, 1:00 PM

North Karelia Wellbeing Services County adopts Nightingale Health’s disease risk assessment as part of public healthcare in Finland

Nightingale Health
New study on benefits of Nightingale blood test in identifying cardiovascular disease risk
Analyst Comment12/18/2025, 8:14 AM by
Antti Luiro, Antti Siltanen

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

A new study shows that the company's blood test can improve the detection of risk factors for heart attacks and strokes.

Nightingale Health
Press release12/17/2025, 7:30 AM

Landmark study: Nightingale Health’s blood test can improve prevention of heart attacks and strokes by 44% compared to current clinical practice

Nightingale Health
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Changes in Nightingale’s management team continue
Analyst Comment12/15/2025, 7:59 AM by
Antti Luiro, Antti Siltanen

Changes in Nightingale’s management team continue

In light of the news, Nightingale is rebuilding its management team to better accelerate growth in its healthcare business.

Nightingale Health
Regulatory press release12/12/2025, 12:55 PM

Nightingale Health Plc restructures Management Team to accelerate healthcare business growth

Nightingale Health
Nightingale's CFO departs suddenly
Analyst Comment12/9/2025, 5:53 AM by
Antti Luiro, Antti Siltanen

Nightingale's CFO departs suddenly

The rapid change came as a surprise to us and appears to have occurred at the company's initiative, although the exact reasons remain unclear due to the concise announcement.

Nightingale Health
Regulatory press release12/8/2025, 8:35 AM

Change in Nightingale Health Plc’s Management Team

Nightingale Health
Nightingale expands its strategic partnership with Terveystalo
Analyst Comment11/27/2025, 9:12 AM by
Antti Luiro

Nightingale expands its strategic partnership with Terveystalo

With the new agreement, Nightingale's blood analysis technology will be made available to all Terveystalo customer groups, whereas previously it has mainly been used in health check-ups for occupational health customers.

Nightingale Health
Press release11/26/2025, 9:00 AM

Terveystalo and Nightingale Health deepen strategic partnership – preventive healthcare available to all Terveystalo customers in Finland

Nightingale Health
Press release11/20/2025, 8:00 AM

Nightingale Health enables access to world’s largest metabolomics dataset through UK Biobank collaboration

Nightingale Health
Regulatory press release11/6/2025, 3:10 PM

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Nightingale Health
Nightingale strengthens its research offering through strategic partnership
Analyst Comment11/5/2025, 2:59 PM by
Antti Luiro, Antti Siltanen

Nightingale strengthens its research offering through strategic partnership

Through this partnership, Nightingale will integrate Alamar's brain health proteomics technology into its multiomics offering.

Nightingale Health
Forum discussions
It’s quite quiet in this thread. Results here: Inderes Nightingale Healthin puolivuotiskatsaus: Kliinistä arvoa terveydenhuollolle... Nightingale Health Oyj | Pörssitiedote | 05.03.2026 klo 09:00:00 EETNightingale Health -konsernin puolivuotiskatsaus 1.7.2025–31.12.2025 (tilintarkastamaton...
yesterday
by Mika
8
I read it and watched the webinar. The guidance is being maintained because, in practice, orders are at 50% growth. Nothing from the Aalborg deal was recognized as revenue in H1 yet, and they expect that it could all be recognized in H2. Therefore, if the guidance is met, the rest...
yesterday
by Puutaheinää
7
The IT strategy consultant was spouting jargon again. After watching the Boston Heart webinar last May, I noted that Jeffrey Barrett was the first company representative who was able to explain the clinical significance of the test results. But now he is leaving (or has he already...
23 hours ago
by omegaalpha
4
I don’t know, Suna’s interview left me a bit speechless. Somehow the spark was missing from the man. Even the pipelines weren’t top-notch like they usually are. As a shareholder, I’d like to be wrong, but it feels like they’re always charging ahead with great intensity in some direction...
yesterday
by Cle
3
There is also another side to the matter – who will take over? New and energetic expertise is needed and it exists, but will they meet?
yesterday
by Prototyping
2
Regarding that cash, it was mentioned that there is about 2M in extra burn due to the Helsinki premises. If you subtract that and assume that sales grow, reducing the burn, it might last for three years. This company really has an unfortunately high ratio of fixed to variable costs...
yesterday
by Puutaheinää
2
I’ll quickly comment on that robo-comment from our trusted analysis firm. “What is noteworthy, however, is the decrease in net cash to EUR 37.9 million (June 30, 2025: EUR 47.6 million), meaning the cash burn in the H1 period was approximately EUR 9.7 million. At the current burn...
yesterday
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
2
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.